Synergistic Inhibition of PI3K and Shh Pathways Induces Mitotic Catastrophe and Apoptosis in PTEN-Deficient Glioblastoma

The identification of molecular vulnerabilities in glioblastoma (GBM) has driven efforts to develop targeted therapies, yet clinical success remains limited. This study demonstrates that PTEN-deficient GBMs exhibit a unique dependency on the coordinated activation of both PI3K and Sonic hedgehog (Shh) signaling pathways. While inhibition of either pathway alone provides only modest benefit, dual targeting results in profound antitumor effects through the induction of mitotic catastrophe and apoptosis. The therapeutic rationale is grounded in genomic data showing that low PTEN expression correlates with elevated levels of gli1 and gli2, key transcription factors in the Shh pathway. This coordinate activation suggests a functional interdependence between the two cascades, which we now show is exploitable for therapy.

In vitro experiments using patient-derived GBM neurosphere cultures revealed that single-agent inhibitors of PI3K (BKM120) or Shh (LDE225) had minimal impact on viability in PTEN-deficient cells. However, combination treatment led to a dramatic, synergistic reduction in cell survival across multiple lines. Time-lapse imaging of labeled tumor cells demonstrated that combination therapy not only suppressed proliferation but also significantly increased cell death over time. These effects were confirmed by immunostaining for activated caspase-3 in vitro and TUNEL assays in vivo, indicating robust apoptosis. Notably, the combination induced severe mitotic defects, including abnormal spindle formation with chromosomes arranged in rosette-like patterns around central centrosomes—hallmarks of mitotic catastrophe. Many dividing cells produced two daughter cells that rapidly died, underscoring the catastrophic nature of the response.

Mechanistically, the combination therapy effectively blocked phosphorylation of Akt and S6 kinase (S6K), key mediators of PI3K and mTOR signaling. S6K emerged as a critical convergence node: its activity was enhanced by both PI3K and Shh signaling, and its inhibition alone reduced cell size and viability. Stimulation of Smoothened with SAG increased pS6 levels, confirming Shh’s role in S6K activation. Conversely, direct inhibition of S6K with PF 4708671 recapitulated the antitumor effects of combination therapy, reinforcing its central role. Additionally, combination treatment synergistically downregulated cyclin D1, a protein regulated by both PI3K and Shh pathways, further disrupting cell cycle progression.

Genome-wide microarray analysis of treated tumors identified widespread changes in gene expression, including genes linked to prognosis and pathway regulation. These findings confirm that dual inhibition leads to broad biological reprogramming beyond simple pathway suppression. Importantly, the efficacy of the combination was strictly dependent on PTEN deficiency; restoration of PTEN expression or knockdown in PTEN-expressing lines abolished sensitivity, confirming the causal link.

In vivo, orthotopic xenograft models using luciferase-expressing hBT112 and hBT145 GBM cells showed that combination therapy dramatically suppressed tumor growth compared to monotherapies or vehicle controls. Bioluminescence imaging revealed stable signal levels throughout the study, indicating sustained tumor control. MRI and histopathological analyses confirmed significant reductions in tumor volume and dissemination, with fewer human NuMA-positive cells infiltrating surrounding brain tissue.Benzil manufacturer Surviving animals treated with the combination exhibited lower tumor burden at late time points, suggesting durable responses.4-Nitrothalidomide In stock

These results highlight the importance of targeting both PI3K and Shh pathways simultaneously in PTEN-deficient GBM.PMID:33998995 The observed mitotic catastrophe and apoptosis represent a powerful mechanism of tumor cell elimination that cannot be achieved by single-pathway inhibition. Given that BKM120 and LDE225 are already in clinical trials with favorable pharmacokinetic profiles and blood-brain barrier penetration, this combination offers immediate translational potential. Future clinical strategies should incorporate biomarker-driven patient selection based on PTEN status and pS6K levels to optimize outcomes. This work establishes a new paradigm for precision therapy in glioblastoma, where combinatorial targeting of interconnected oncogenic pathways yields superior efficacy.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com